Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia

Anna Hecht, Daniel Nowak, MD, Florian Nolte, Verena Nowak, Julia Oblaender, Thomas Buechner, Karsten Spiekermann, Wolf-Karsten Hofmann, MD, Eva Lengfelder, MD

Blood (2015) 126 (23): 1382.

https://doi.org/10.1182/blood.V126.23.1382.1382

Published: 2015

Journal Articles

Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

Blood (2015) 126 (23): 2517.

https://doi.org/10.1182/blood.V126.23.2517.2517

Published: 2015

Journal Articles

Identification of Recurrent Submicroscopic Deletions of chromosome1q31.3 As Possible Molecular Prognostic Markers in Acute Promyelocytic Leukemia (APL)

Blood (2011) 118 (21): 420.

https://doi.org/10.1182/blood.V118.21.420.420

Published: 2011

Journal Articles

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.

Friederike Schneider, Annika Dufour, Tobias Benthaus, Stephanie Schneider, Gudrun Mellert, Evelyn Zellmeier, Stefan K Bohlander, Michael Unterhalt, Michaela Feuring-Buske, Christian Buske, Jan Braess, Maria Cristina Sauerland, Achim Heinecke, Wolfgang Berdel, Thomas Buechner, Bernhard Wörmann, Wolfgang Hiddemann, Karsten Spiekermann, Eva Hoster

Blood (2009) 114 (22): 2635.

https://doi.org/10.1182/blood.V114.22.2635.2635

Published: 2009

Journal Articles

Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

Felix Rosenow, Gerda Silling, MD, Berkemeier Almut, MD, Carsten Mueller-Tidow, MD, Steffen Koschmieder, MD, Guido Bisping, MD, Utz Krug, MD, Thomas Buechner, MD, Wolfgang E Berdel, MD, Joachim Kienast, MD, Matthias Stelljes, MD

Blood (2009) 114 (22): 3317.

https://doi.org/10.1182/blood.V114.22.3317.3317

Published: 2009

Journal Articles

High Expression of Lymphoid Enhancer-Binding Factor 1 ( LEF1 ) Is a Novel, Favorable Prognostic Marker in Cytogenetically Normal AML and Is Associated with Upregulation of T-Lymphoid Lineage Markers in AML Blasts.

Klaus H. Metzeler, Bernhard Heilmeier, Konstantin Petropoulos, Maria C. Sauerland, Achim Heinecke, Wolfgang E Berdel, Thomas Buechner, Jan Braess, Karsten Spiekermann, Michaela Feuring-Buske, Wolfgang Hiddemann, Stefan K Bohlander, Christian Buske

Blood (2009) 114 (22): 398.

https://doi.org/10.1182/blood.V114.22.398.398

Published: 2009

Journal Articles

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Blood (2009) 113 (21): 5250–5253.

https://doi.org/10.1182/blood-2008-09-172668

Published: 2009

Includes: Supplemental data

Journal Articles

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

Friederike Schneider, Eva Hoster, Michael Unterhalt, Stephanie Schneider, Annika Dufour, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, Michaela Feuring-Buske, Christian Buske, Jan Braess, Achim Heinecke, Maria C. Sauerland, Wolfgang E. Berdel, Thomas Buechner, Wolfgang Hiddemann, Karsten Spiekermann

Blood (2008) 112 (11): 2531.

https://doi.org/10.1182/blood.V112.11.2531.2531

Published: 2008

Journal Articles

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

Friederike Schneider, Eva Hoster, PhD, Marietta Rottenkolber, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Tobias Benthaus, Gudrun Mellert, Evelyn Zellmeier, Stefan K. Bohlander, MD, Michael Unterhalt, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Jan Braess, MD, Achim Heinecke, PhD, Wolfgang E. Berdel, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3482.

https://doi.org/10.1182/blood.V110.11.3482.3482

Published: 2007

Journal Articles

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Stephanie Schneider, PhD, Friederike Schneider, Annika Dufour, PhD, Gudrun Mellert, Evelyn Zellmeier, Jan Braess, MD, Stefan K. Bohlander, MD, Michaela Feuring-Buske, MD, Christian Buske, MD, Susanne Fritsch, Achim Heinecke, PhD, Maria C. Sauerland, PhD, Eva Hoster, PhD, Michael Unterhalt, MD, Wolfgang E. Berdel, MD, Bernhard J. Wormann, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2007) 110 (11): 3486.

https://doi.org/10.1182/blood.V110.11.3486.3486

Published: 2007

Journal Articles

Role of CEBPA-Mutations in AML with Prognostically Intermediate Cytogenetics: Data of the AMLCG Study Group and Gene Expression Analyses.

Susanne Schnittger, PhD, Viola Conrad, Alexander Kohlmann, Martin Dugas, MD, Sylvia Merk, Wolfgang Kern, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Claudia Schoch, MD, Torsten Haferlach, MD

Blood (2004) 104 (11): 571.

https://doi.org/10.1182/blood.V104.11.571.571

Published: 2004

Journal Articles

The Investigation of Molecular Markers in the Prognostically Intermediate Karyotype Group in AML Provides Clinically Relevant Information.

Susanne Schnittger, PhD, Claudia Schoch, MD, Viola Conrad, Wolfgang Kern, MD, Thomas Buechner, MD, Wolfgang Hiddemann, MD, Torsten Haferlach, MD

Blood (2004) 104 (11): 1973.

https://doi.org/10.1182/blood.V104.11.1973.1973

Published: 2004

Journal Articles

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

Martin B. Steins, Teresa Padró, Ralf Bieker, Sandra Ruiz, Martin Kropff, Joachim Kienast, Torsten Kessler, Thomas Buechner, Wolfgang E. Berdel, Rolf M. Mesters

Blood (2002) 99 (3): 834–839.

https://doi.org/10.1182/blood.V99.3.834

Published: 2002

NARROW

Different Impact of Expression Levels of IGFBP2 and IGFBP7 on Survival and Relapse Rate in Acute Promyelocytic Leukemia

Higher Incidence of Secondary AML and Adverse Molecular Markers, Together with Lower CR and Higher AML Related Death Rates in Elderly Compared to Younger Patients: Results from 2435 Patients Included in the Two German AML Intergroup Studies

Identification of Recurrent Submicroscopic Deletions of chromosome1q31.3 As Possible Molecular Prognostic Markers in Acute Promyelocytic Leukemia (APL)

A New Molecular and Clinical Prognostic Score for Risk Stratification in CN-AML.

Immunological Intervention Triggered by Decreasing CD34 + Lineage-Specific Donor Cell Chimerism to Prevent Relapse of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT).

High Expression of Lymphoid Enhancer-Binding Factor 1 ( LEF1 ) Is a Novel, Favorable Prognostic Marker in Cytogenetically Normal AML and Is Associated with Upregulation of T-Lymphoid Lineage Markers in AML Blasts.

NPM1 but not FLT3-ITD mutations predict early blast cell clearance and CR rate in patients with normal karyotype AML (NK-AML) or high-risk myelodysplastic syndrome (MDS)

Age-Dependent Frequencies of NPM-1/FLT3-ITD Mutations in Patients with Normal Karyotype AML

Prognostic Impact of Clinical and Molecular Markers in Normal Karyotype AML-Results from the AMLCG 2000 Trial.

FLT3-ITD but Not FLT3-TKD Mutations Have Major Prognostic Impact in Normal Karyotype AML.

Role of CEBPA-Mutations in AML with Prognostically Intermediate Cytogenetics: Data of the AMLCG Study Group and Gene Expression Analyses.

The Investigation of Molecular Markers in the Prognostically Intermediate Karyotype Group in AML Provides Clinically Relevant Information.

Efficacy and safety of thalidomide in patients with acute myeloid leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only